Actively Recruiting
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
Led by Mclean Hospital · Updated on 2026-05-13
80
Participants Needed
1
Research Sites
246 weeks
Total Duration
On this page
Sponsors
M
Mclean Hospital
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Many people with depression do not get better with standard treatments like medication. One promising alternative is transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic pulses to stimulate specific brain regions. A particular pattern of TMS called continuous theta-burst stimulation (cTBS) is thought to reduce overactive brain activity in depression, but the investigators do not yet fully understand how it works at the level of brain cells and connections. This study aims to determine the biological mechanism by which cTBS changes brain activity in people with depression. Specifically, the investigators are testing two competing ideas: (1) that cTBS works by weakening the connections between brain cells through a process called long-term depression (LTD), which is driven by a chemical messenger system called glutamate; or (2) that cTBS works by increasing the brain's natural "braking" system, driven by a different chemical messenger called GABA. To test these ideas, participants with depression will receive cTBS along with one of four FDA-approved medications, or placebo, that either boost or block these chemical messenger systems. The investigators will measure changes in brain activity using electroencephalography (EEG) recorded simultaneously with TMS. Specific patterns in the EEG signal, called TMS-evoked potentials (TEPs), act as a window into how different brain cell types are responding to stimulation. Each participant will complete four study visits, each testing a different drug-TMS combination in random order. One group of participants will test drugs targeting the glutamate system (d-cycloserine and memantine). A second group will test drugs targeting the GABA system (lorazepam and baclofen). All drugs are given as a single oral dose and are commonly used in clinical practice. Understanding exactly how cTBS works at a biological level could open the door to more effective, personalized TMS treatments.
CONDITIONS
Official Title
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Can safely receive TMS and study drugs
- Stable medication regimen for one month prior to study participation and throughout the study
- Not currently receiving TMS, ECT, or ketamine treatments
- No active safety concerns related to suicidality
- Moderate to severe Major Depressive Disorder confirmed by specific questionnaires
You will not qualify if you...
- History of seizures or epilepsy
- History of intracranial pathology or brain lesions
- History of traumatic brain injury with loss of consciousness over 15 minutes
- Signs of increased intracranial pressure
- Major neurological conditions such as recent stroke, tumor, or neurodegenerative disorders
- Major medical conditions that increase risk of emergency during a seizure (e.g., cardiac issues, asthma)
- Severe migraines causing intolerance to treatment
- Unable to tolerate MRI procedures
- Pregnancy
- Known allergy to d-cycloserine, baclofen, memantine, or lorazepam
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
Actively Recruiting
Research Team
P
Prem Ganesh, MS
CONTACT
D
Dennis W Guevara
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here